PEOR

PHARMACOECONOMICS & OUTCOMES RESEARCH SOCIETY

جمعية اقتصاديات الدواء والمخرجات الصحية

EVIDENCE GENERATION AND SYNTHESIS METHODS IN HTA

8-12TH | FEBRUARY 2025

Crowne Plaza Riyadh Palace

Project Partnership

CCHO
ACCESS TO MEDICINE

PEOR
PHARMACOECONOMICS & OUTCOMES RESEARCH SOCIETY
جمعية اقتصاديات الدواء والمخرجات الصحية

ISPOR
Saudi Arabia
Chapter

PEOR
PHARMACOECONOMICS & OUTCOMES RESEARCH SOCIETY
جمعية اقتصاديات الدواء والمخرجات الصحية

CCHO
ACCESS TO MEDICINE

ISPOR
Saudi Arabia
Chapter

EVIDENCE GENERATION AND SYNTHESIS METHODS IN HEALTH TECHNOLOGY ASSESSMENT (HTA) WORKSHOP

Speakers

Dr Randa Attieh, PhD

Scientific Counselor, INESS, Canada

Howard Friedman, PhD

Chief Data scientist, Health Economist, Adjunct Professor , Columbia University, United States.

Prakash Navaratnam, PhD

Senior Advisor on HEOR, United States

Dr. Fatima AlSayah, PhD

Principal & PROMs Lead, CCHO, Canada

Elly Stolk, PhDPhD

Scientific Director at EuroQol, Professor at Erasmus School of Health Policy & Management (ESHPM) , The Netherlands

Richard Chapman, PhD

Chief Scientific Officer of the Center of Innovation & Value Research , United States

Nimer Alkhatib, PhD

Founder and General Manager of Path Economics, LLC

Steve Williamson, PhD

Associate Director for Managed Access, including the Cancer Drugs Fund (CDF), (IMF) and the (EVA) of Healthtech, England

Pilar Pinilla-Dominguez, PhD

Associate Director of the NICE International and Education Services within NICE Advice, Spain

Dalia Dawoud, PhD

Associate Director at the National Institute for Health and Care Excellence, Egypt

Moderators

Christiane Maskineh, PhD

CEO of CCHO, United Arab Emirates

Mirna Matni, PharmD

Director Health Policy & Payer Insights, CCHO, United Arab Emirates

Yazed Alruthia, PhD

Professor, Pharm.D, King Saud University, Saudi Arabia

Mai Alsaqa'aby, MSc

Professor, Pharm.D, King Saud University, Saudi Arabia

Anas Hamad, PhD

Director of Pharmacy Department at National Center for Cancer Care , Director of ISPOR Qatar chapter, Qatar

Omar Al Mohammed, PhD

Professor, King Saud University, Saudi Arab

Abdulaali Almutairi, PhD

Senior Chief Drug Safety Expert at the Saudi Food and Drug Authority (SFDA), Saudi Arabia

Bander Balkhi, PhD

Professor, King Saud University, Saudi Arabia

PEOR
PHARMACOECONOMICS & OUTCOMES RESEARCH SOCIETY
جمعية اقتصاديات الدواء والمخرجات الصحية

CCHO
ACCESS TO MEDICINE

ISPOR
Saudi Arabia
Chapter

Scientific Committee

Yazeed Al Ruthia, PhD
Professor, Pharm.D,
King Saud University,
Saudi Arabia



Afnan Alrasheed
King Faisal Specialist Hospital and Research Centre, Riyadh | clinical Pharmacist | Pharmaceutical Care Division

Omar Almohammed, PhD
Professor, King
Saud University,
Saudi Arab

Bander Balkhi, PhD
Professor, King
Saud University,
Saudi Arabia

Abdulaali Almutairi, PhD
Senior Chief Drug Safety Expert at the Saudi Food and Drug Authority (SFDA), Saudi Arabia

Logistics Committee

Dr. Mai Alsaqa'aby, MSc.
Professor, Pharm.D,
King Saud University,
Saudi Arabia

Hassan Assairi
Key Account Manager

Nasser Mohammed Khodah
PharmD, Rph

Sondus Issam Ata
B.Pharm, M.Pharm,
Senior Pharmacist,
QPPV, RCP-SNIH

Yara AlJadeed
PharmD, Regulatory Affairs and Pharmacovigilance Specialist

Areej Maher Sawalha
MLS
Medical laboratory specialist

Media Committee

Majd Abdullah Alshamrani
PharmD, MBA Sr. Regulatory Affairs
Media & PR Lead - ISPOR Saudi

Shaden Almohawwes
Media Team

Alya Alabdulrahim
Media Coordinators

Alanoud Alabdulrahim
Media Coordinators

Nada Alotaibi
Media Coordinators

Lea Ghajar
Pharm.D
Research Associate at CCHO

Ohud Alsudyyes
Media team

Haya Altamimi
Media Team

Roaa Akkam
Media Team

Nour Choueiry
Pharm.D, MBA.
Marketing Communication Manager at CCHO

PEOR
PHARMACOECONOMICS & OUTCOMES RESEARCH SOCIETY
جمعية اقتصاديات الدواء والمخرجات الصحية

CCHO
ACCESS TO MEDICINE

ISPOR
Saudi Arabia
Chapter

Dr Randa Attieh, PhD

Scientific Counselor,
INESS, Canada

Dr. Attieh, a PhD holder in Public Health from Université Laval, Québec, Canada, with expertise in health innovation and system management. She has extensive experience in health care decision-making, HTA, knowledge translation, and implementing evidence-based interventions. Since 2016, she has consulted for organizations like WHO and The Lebanese Ministry of Public Health. Dr.Attieh is also part of the Lebanese National Committee for Breast Cancer Awareness.

Howard Friedman, PhD

Chief Data scientist, Health Economist,
Adjunct Professor , Columbia University,
United States.

Dr. Friedman, Chief Data Scientist, leads experts in health economics and outcomes research across various industries. He is an Adjunct Professor at Columbia University and an author of books on data science and public health. With over 100 scientific papers. Dr.Friedman is recognized globally as a leader in data science. Fluent in multiple languages, he uses data to create meaningful global

Prakash Navaratnam, PhD

Senior Advisor on
HEOR, United States

Dr. Navaratnam, a healthcare expert with over 30 years of experience, holds an MPH in Biostatistics and Epidemiology, and a Ph.D. in Health Services Administration from the Ohio State University. He serves as an adjunct Clinical Assistant Professor and executive faculty mentor at the university. As a senior advisor on health economics and outcomes research, he collaborates globally with life sciences and digital health companies and fosters research and education partnerships between institutions in Asia, the U.S., and Europe.

Dr. Fatima AlSayah, PhD

Principal & PROMs Lead, CCHO,
Canada

Dr. Al Sayah, is an expert in patient-reported outcomes and quality of life measurement, she applies her work to clinical research, population health, and cost- effectiveness studies. Dr. Al Sayah is also a health outcomes researcher at the University of Alberta's School of Public Health. A EuroQol Group member with over 70 publications, she is Associate Editor of Health and Quality of Life Outcomes and a reviewer for top journals like Quality of Life Research and Value in Health.

Dr. Elly Stolk, PhD

Professor at Erasmus School of Health Policy & Management (ESHPM) , The Netherlands

Dr. Stolk is the Scientific Director at EuroQol. She has over two decades of experience in health technology assessment, health economics, and quantitative research. Dr. Stolk is a recognized leader in advancing health policy and services evaluation. She has held roles as Scientific Team Leader at EuroQol and Assistant Professor at Erasmus University and Erasmus MC, demonstrating strong expertise in academic writing, clinical research, and health services research has context menu

Dr Richard Chapman, PhD

Chief Scientific Officer of the Center of Innovation & Value Research , United States

Dr. Chapman is the Chief Scientific Officer of the Center for Innovation and Value Research, a non- profit research organization focused on improving value assessment in healthcare. Formerly, director of Health Economics at ICER. Dr. Chapman has developed economic evaluation, accompanying clinical evidence reviews, assessing the potential costs, cost- effectiveness and budget impact of a wide range of pharmaceutical and other clinical interventions. His academic credentials include a PhD Degree in Health Policy, with a specialization in decision sciences, from Harvard University. He also holds a master's degree in health policy and management from the Harvard School of Public Health.

PEOR
PHARMACOECONOMICS & OUTCOMES RESEARCH SOCIETY
جمعية اقتصاديات الدواء والمخرجات الصحية

CCHO
ACCESS TO MEDICINE

ISPOR
Saudi Arabia
Chapter

Nimer Alkhatib, PhD

Founder and General
Manager of Path Economics, LLC

Nimer has over 15 years of experience in healthcare across the USA, Europe, and the Middle East. He earned his PharmD from the Jordan University of Science and Technology in 2011 and later completed his Master's and PhD in Pharmaceutical Sciences, focusing on pharmaceutical economics and outcomes research, at the University of Arizona. He has worked as a health economic analyst and consultant for various healthcare agencies and pharmaceutical companies, and has led key projects for organizations like the Department of Health Services (Arizona) and Banner University Hospital. Nimer has published over 57 articles in high-tier journals, including JAMA and Blood, and serves as an editor for the Journal of Medical Economics. He is currently an assistant professor at Al-Zaytoonah University of Jordan and founder of Path Economics, LLC, specializing in evidence-based health economics and outcomes research. His work focuses on healthcare value and value-based pricing.

Steve Williamson, PhD

Associate Director, Managed Access

Dr. Steve Williamson is NICE's Associate Director for Managed Access, overseeing the Cancer Drugs Fund (CDF), Innovative Medicines Fund (IMF), and Early Value Assessment (EVA) of Healthtech. His team collaborates with NHS England to develop and deliver Managed Access. A pharmacist with expertise in oncology, commissioning, and HTA implementation, Steve was NHS England's National Lead Cancer Pharmacist for five years and previously a Consultant Cancer Pharmacist. He is a past Chair of the British Oncology Pharmacy Association, has authored national guidelines, teaches on Newcastle University's Oncology MSc, and has published research on cancer medicines and chemotherapy service delivery.

Pilar Pinilla-Dominguez, PhD

Associate Director, NICE International and Education Services – NICE Advice

Dr. Pilar PinillaDominguez is Associate Director of NICE International and Education Services, leading strategy and oversight while delivering international workshops, seminars, and consultancy projects. She also advises the life sciences industry on evidence generation. Since joining NICE in 2012, she has worked in Technology Appraisals and Highly Specialised Technologies. Previously, she was a researcher at SESCS, conducting systematic reviews and economic evaluations for the Spanish Healthcare System. She holds a degree in Business Administration (University of La Laguna) and an MSc in Health Economics (Erasmus University). Pilar is an Associate Editor of Gaceta Sanitaria and second Vice President of AES.

Dalia Dawoud, PhD

Associate Director, Science, Policy and Research, NICE

Prof. Dalia Dawoud, PhD, is Associate Director (Research) at NICE, leading the HTA Innovation Lab and European Commission-funded projects worth over €5M. A health economist with 20+ years of experience, she focuses on advancing HTA and clinical guideline methods. Widely published in health economics, she is Associate Editor of Value in Health and a Director on ISPOR's Board (2023–2026). She is also a Professor of Clinical Pharmacy at Cairo University and has extensive experience in the Egyptian healthcare system.

PEOR
PHARMACOECONOMICS & OUTCOMES RESEARCH SOCIETY
جمعية اقتصاديات الدواء والمخرجات الصحية

CCHO
ACCESS TO MEDICINE

ISPOR
Saudi Arabia
Chapter

AGENDA – DAY 1
EVIDENCE GENERATION IN HTA

Time	Title	Moderator & Speaker
9:00-9:30	Registration & Welcome	**Moderators:** Dr. Mai Alsaqa'aby, MSc. Dr. Anas Hamad, PhD Dr. Yazeed Al Ruthia, PhD **Speaker:** Dr. Randa Attieh, PhD
9:30-10:00	Introduction & Objectives	
10:00-11:30	Evidence Hierarchy and Systematic Reviews Overview . Levels of Evidence: Randomized vs. non-randomized studies . Role of Systematic Reviews in evidence synthesis Evidence Analysis and Synthesis · Qualitative analysis (narrative analysis) · Quantitative analysis: Direct comparison studies (RCTs) V Indirect comparison (types of meta-analysis, Fixed effect model) . Types of outcomes: RR, HR, RRR, OR . Methodological quality (Cochrane risk of bias) GRADE Methodology: Understanding and applying the GRADE framework for evidence quality Handling heterogeneity . Exploring and understanding heterogeneity . Solutions and models: Random effect models and their pros and cons	
11:30-12:00	**Coffee Break/Network**	
12:00- 13:30	**Case Study**	**Speaker:** Dr. Randa Attieh, PhD
13:30-14:30	**Lunch Time**	
14:30-15:30	Real-World Data (RWD) and Real-World Evidence (RWE) . Introduction to RWD & RWE, and their complementary nature Global Data Collection and AI . Applications of big data in evidence production . Role of AI in enhancing data analysis Addressing Limitations and Uncertainty . Limitations of conventional data generation methods . Strategies for dealing with uncertainty ISPOR AMCP-NPC Checklist	**Speaker:** Dr. Howard Friedman, PhD Dr. Prakash Navaratnam, PhD
15:30-16:00	Quiz Q&A	Dr. Randa Attieh, PhD

AGENDA – DAY 2

PATIENT REPORTED OUTCOMES IN HTA

Time	Title	Moderator & Speaker
9:00-9:30	Registration & Welcome	Moderator
9:30-10:00	Introduction & Objectives	Moderator
10:00-11:30	Introduction to PROS . Overview of PROs and their significance in healthcare and research . PROMs and PREMs Types of PRO Measures . Generic vs. disease-specific measures . Profile vs. preference-based measures Criteria for Selecting PRO measures for various applications . Overview of psychometric evidence (validity, reliability, responsiveness) . Practical considerations (e.g., language, administration modes and formats, length of measure) Role of PROs in HTA . Calculating QALYs . Outcome measure	**Moderators:** Dr. Omar Almohammed,PhD Dr. Christiane Maskineh, PhD Dr. Yazeed Al Ruthia, PhD **Speaker:** Dr. Fatima Al Sayah, PhD
11:30-12:00	**Coffee Break/Network**	
12:00- 13:30	Case Studies . Case Study: PROs . Case Study: Patient Satisfaction and Adherence	**Speaker:** Dr. Fatima Al Sayah, PhD
13:30-14:30	**Lunch Time**	
14:30-15:30	International Use of the EQ-5D . The role of EQ-5D in HTA . Overview of the New Saudi EQ-5D Value Set	**Speaker:** Dr. Elly Stolk, PhD
15:30-16:00	Quiz Q&A	**Speaker:** Dr. Fatima Al Sayah, PhD

AGENDA – DAY 3
ECONOMIC EVIDENCE IN HTA

Time	Title	Moderator & Speaker
9:00-9:30	Registration & Welcome	**Moderators:** Dr. Mirna Matni, PhamrD; Dr. Abdulaali Almutairi, PhD; Dr. Yazeed Al Ruthia, PhD **Speaker:** Dr. Richard Chapman, PhD
9:30-10:00	Introduction & Objectives	
10:00-11:30	Introduction to Efficacy Outcomes in Economic Evaluation . Intermediate outcomes vs. comprehensive measures Concept of Utility in Health Economic Evaluations . Introduction to utility and its role in economic evaluations . Stages of estimating Quality-Adjusted Life Years (QALYs) . Alternatives to QALYs: Disability-Adjusted Life Years (DALYs) ISPOR Guidelines for Health-State Utility Mapping	
11:30-12:00	**Coffee Break/Network**	
12:00- 13:30	Case Study Q&A	**Speaker:** Dr. Richard Chapman, PhD
13:30-14:30	**Lunch Time**	
14:30-15:30	Value Assessment Frameworks: A Review Patient-Informed Value Elements · Definition, prioritization, refinement, and synthesis Case Studies	**Speaker:** Dr. Richard Chapman, PhD
15:30-16:00	Quiz Q&A	**Speaker:** Dr. Richard Chapman, PhD

AGENDA – DAY 4

BUDGET IMPACT MODEL ADAPTATION: STEP BY STEP IMPLEMENTATION

Time	Title	Moderator & Speaker
9:00-9:30	Registration & Welcome	
9:30-10:00	Introduction & Objectives	**Moderators:** Dr. Bander Balkhi, PhD; Dr. Mai Alsaqa'aby, MSc.; Dr. Yazeed Al Ruthia, PhD **Speaker:** Dr. Nimer Alkhatib, PhD
10:00-11:30	Introduction to Economic Models . Types of economic models Budget Impact Model Implementation · Objectives/ perspective . Required data · Cost data · Time horizon ISPOR Guidelines for BIM adaptation	
11:30-12:00	**Coffee Break/Network**	
12:00- 13:30	**Case Study Q&A**	**Speaker:** Dr. Nimer Alkhatib, PhD
13:30-14:30	**Lunch Time**	
14:30-15:30	Technical examples: Oncology model Diabetes models	**Speaker:** Dr. Nimer Alkhatib, PhD
15:30-16:00	Quiz Q&A	

AGENDA – DAY 5

MANAGED ENTRY AGREEMENTS (MEA)

Time	Title	Moderator & Speaker
9:00-9:30	Registration & Welcome	**Moderators:** Dr. Christiane Maskineh, PhD Dr. Mirna Matni, PharmD Dr. Yazeed Al Ruthia, PhD
9:30-11:30	Group assessments and competition	
12:00- 13:00	**Coffee Break/Network**	
13:00-15:00	**Managed Entry Agreement (MEA)**	
13:00-13:30	Introduction about MEA (principles and application by NICE)	**Speaker:** Dr. Yazeed Al Ruthia, PhD
13:30-14:00	Discussion on Outcome Based Pricing (OBP)	**Speaker:** Dr. Steve Williamson
14:00-14:30	Case studies from NICE on orphan medications (SMA, SCD*, rare hematology conditions)	
14:30-14:45	NICE International Support for Capacity Building	**Speaker:** Dr. Pilar Pinilla-Dominguez
14:45-15:00	NICE Research and Policy Activities on Managed Entry Agreement	**Speaker:** Dr. Dalia Dawoud
15:00 - 15:30	Panel Discussion and Q&A	All

PEOR
PHARMACOECONOMICS & OUTCOMES RESEARCH SOCIETY
جمعية اقتصاديات الدواء والمخرجات الصحية

CCHO
ACCESS TO MEDICINE

ISPOR
Saudi Arabia
Chapter

PLATINUM SPONSOR

novo nordisk®

Johnson&Johnson

GOLD SPONSOR

GSK

VERTEX

SILVER SPONSOR

Boston Oncology™

Stemline®
A Menarini Group Company

AMGEN